Rajesh B. Parekh - 07 Jun 2023 Form 4 Insider Report for Aura Biosciences, Inc. (AURA)

Reporting relationship: Director
Issuer ticker: AURA
Reported as of: 07 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2023, 16:56:03 UTC
Prior SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Julie Feder, Attorney-in-fact

Key filing fact

Rajesh B. Parekh filed Form 4 for Aura Biosciences, Inc. (AURA) on 09 Jun 2023.

Key facts

This page summarizes Rajesh B. Parekh's Form 4 filing for Aura Biosciences, Inc. (AURA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2023, 16:56.

Change

Previous filing in this sequence was filed on 17 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +16,000
Change %
Price: $0.000000
Shares after: 16,000
Date: 07 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $12.83
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders.